RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
  AIDS
  Anthrax
  Dengue
  Ebola
  HCV
  Influenza
  Leishmaniasis
  Malaria
  MRSA
  Mumps
  Pertussis
  Prion Diseases
  SARS
  Shigella
  Small Pox
  Tuberculosis
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
AIDS Channel

subscribe to AIDS newsletter
Latest Research : Infectious Diseases : AIDS

   EMAIL   |   PRINT
People with HIV who are given free ART drugs do "significantly" better

Jul 31, 2005 - 1:51:00 PM
Doucette said she was not surprised with the results, except for the fact that people in developing countries who received free ART drugs did so much better--30 per cent higher rates of success--than people who had to pay for their drugs.

 
[RxPG] A new study from the University of Alberta reveals that people with HIV in developing countries do just as well on antiretroviral therapy (ART) programs as do people with HIV on ART programs in developed countries. It also shows that people with HIV who are given free ART drugs will do "significantly" better at fighting the disease compared to those who must pay for the drugs.

"ART programs are complex therapeutic regimens that require patients to take a minimum of three pills a day for the rest of their lives," said Dr. Karen Doucette, a professor in the U of A Division of Infectious Diseases. "It's often difficult for people in North America to maintain the regimens, so some critics believe these programs can't work in resource poor settings, where patients don't have the support--the pharmacists, the social workers, and the physicians, for example--that we have."

However, after reviewing more than 100 research papers on the topic, Doucette and her colleagues concluded ART programs have the same efficacy rates in both developed and non-developed countries. The general success rate in keeping the virus suppressed after being on the program for 12 to 18 months is about 60 per cent. The results are published this month in the journal Clinical Infectious Diseases.

Doucette said she was not surprised with the results, except for the fact that people in developing countries who received free ART drugs did so much better--30 per cent higher rates of success--than people who had to pay for their drugs.

"Although this intuitively makes sense, it was a satisfying surprise to be able to demonstrate the impact of payment for ART on its success. This has important potential implications for ART program development, which is ongoing in many resource-poor settings around the world," Doucette said.

According to the latest numbers from the UN, about 40 million people currently have HIV. The vast majority of these people live in developing countries, with almost 75 per cent living in Sub-Saharan Africa. The UN's goal is to provide at least 3 million people living with HIV/AIDS in low- and middle-income countries with ART by the end of 2005.

The number of people receiving ART has been increasing in every region in the world, with Sub-Saharan Africa doubling the number of people on ART to 500,000 in the past six months. As of June 2005, about 1 million people are on ART. Doucette believes these recent results are encouraging, but she says there must be ongoing political, financial and technical support to keep the trend going.

"Our study shows that there's no reason why people in Africa and other resource-poor settings won't follow ART regimens if they can access the treatments. We just have to make sure that everyone knows this and the support for these programs are strengthened over time," Doucette said.



Publication: Clinical Infectious Diseases Journal
On the web: www.ualberta.ca 

Advertise in this space for $10 per month. Contact us today.


Related AIDS News
4 UCLA stem cell researchers receive CIRM Early Translational grants
Professor Vanessa Hayes awarded for exceptional Africa-related work
Plant-based compound may inhibit HIV
Innovative intervention program improves life for rural women in India living with HIV/AIDS
The American Society for Microbiology honors Baligh Yehia
Thomas J. Coates receives 2013 Elizabeth Fries Health Education Award
Scientists find ethnicity linked to antibodies
2013 Canada Gairdner Global Health Award goes to King Holmes for STD work
Study identifies ways to increase HIV testing, reduce HIV infection
A device to speed up HIV diagnostic test

Subscribe to AIDS Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)